drugset / Trial / NCT06959537
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the best dose of the drugs cyclophosphamide and axatilimab that can be given in combination with the standard dose of retifanlimab to patients with metastatic TNBC.
Timeline
- Start
- 2025-08-13
- Primary completion
- 2027-01-31
- Completion
- 2029-01-31
Outcome
Outcome not reported
Stopped: “PI Request”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axatilimab | Monoclonal antibody | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | Oral |
| Background | Retifanlimab | Monoclonal antibody | — | Intravenous |